You just read:

Mirum Pharmaceuticals Secures $120 Million in Series A Financing to Develop Phase 3-Ready Maralixibat for Rare Liver Diseases

News provided by

Mirum Pharmaceuticals Inc.

Nov 07, 2018, 07:00 ET